Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study

Characteristic

All patients (N = 52)

Gender

 

 Male

52

Age, ya

 

 Mean (SD)

12.4 (9.2)

 Median (min, max)

11.0 (1.3, 51.0)

Age, y, category, n (%)a

 

 <2

1 (2.0)

 2-5

5 (9.8)

 5-10

17 (33.3)

 10-15

16 (31.4)

 15-18

4 (7.8)

 18-29

4 (7.8)

 ≥30

4 (7.8)

Age at diagnosis, Mean (SD)

3.5 (2.7)

Years since diagnosis, y (n = 47)b

 

 Mean (SD)

9.3 (8.4)

 Median (min, max)

6.8 (0.7, 46.9)

 Severe patients

 

 Mean (SD)

6.7 (5.4)

 Median (min, max)

5.2 (0.7, 27.5)

 Attenuated patients

 

 Mean (SD)

14.3 (11.0)

 Median (min, max)

11.9 (1.7, 46.9)

Family history of MPS II

 

 Yes

17 (32.7)

 If yes, prenatal diagnosis

1 (5.9)

 No

31 (59.6)

 Do not know

4 (7.7)

MPS II Classification, n (%)c

 

 Severe (with cognitive impairment)

36 (69.2)

 Attenuated (without cognitive impairment)

16 (30.8)

Living Situation, n (%)

 

 Living with parents

48 (92.3)

 Living alone

3 (5.8)

 Living in an institution during the week

1 (1.9)

  1. aData missing for 1 patient.
  2. bData missing for 5 severe phenotype patients.
  3. cEstimates of the relative prevalence of each MPS II phenotype at any point in time are affected by the higher mortality rates for severe versus attenuated patients, and may vary substantially.